Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer - PubMed (original) (raw)
. 2016 Mar 18;471(4):639-45.
doi: 10.1016/j.bbrc.2016.02.072. Epub 2016 Feb 18.
Affiliations
- PMID: 26902121
- DOI: 10.1016/j.bbrc.2016.02.072
Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer
Min Yu et al. Biochem Biophys Res Commun. 2016.
Abstract
Targeting mitochondrial biogenesis has become a potential therapeutic strategy in cancer due to their unique metabolic dependencies. In this study, we show that levofloxacin, a FDA-approved antibiotic, is an attractive candidate for breast cancer treatment. This is achieved by the inhibition of proliferation and induction of apoptosis in a panel of breast cancer cell lines while sparing normal breast cells. It also acts synergistically with conventional chemo drug in two independent in vivo breast xenograft mouse models. Importantly, levofloxacin inhibits mitochondrial biogenesis as shown by the decreased level of mitochondrial respiration, membrane potential and ATP. In addition, the anti-proliferative and pro-apoptotic effects of levofloxacin are reversed by acetyl-L-Carnitine (ALCAR, a mitochondrial fuel), confirming that levofloxacin's action in breast cancer cells is through inhibition of mitochondrial biogenesis. A consequence of mitochondrial biogenesis inhibition by levofloxacin in breast cancer cells is the deactivation of PI3K/Akt/mTOR and MAPK/ERK pathways. We further demonstrate that breast cancer cells have increased mitochondrial biogenesis than normal breast cells, and this explains their different sensitivity to levofloxacin. Our work suggest that levofloxacin is a useful addition to breast cancer treatment. Our work also establish the essential role of mitochondrial biogenesis on the activation of PI3K/Akt/mTOR and MAPK/ERK pathways in breast cancer cells.
Keywords: Breast cancer; Levofloxacin; MAPK/ERK; Mitochondrial biogenesis; PI3K/Akt/mTOR.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
- Therapeutic effects of antibiotic drug mefloquine against cervical cancer through impairing mitochondrial function and inhibiting mTOR pathway.
Li H, Jiao S, Li X, Banu H, Hamal S, Wang X. Li H, et al. Can J Physiol Pharmacol. 2017 Jan;95(1):43-50. doi: 10.1139/cjpp-2016-0124. Epub 2016 Aug 11. Can J Physiol Pharmacol. 2017. PMID: 27831748 - Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through inducing mitochondrial dysfunction and oxidative damage.
Song M, Wu H, Wu S, Ge T, Wang G, Zhou Y, Sheng S, Jiang J. Song M, et al. Biomed Pharmacother. 2016 Dec;84:1137-1143. doi: 10.1016/j.biopha.2016.10.034. Epub 2016 Oct 22. Biomed Pharmacother. 2016. PMID: 27780143 - 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM, Narayanan R, Lu Y, Hurh E, Coss CC, Barrett CM, Miller DD, Dalton JT. Li CM, et al. Int J Oncol. 2010 Oct;37(4):1023-30. Int J Oncol. 2010. PMID: 20811725 - mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.
O'Regan R, Hawk NN. O'Regan R, et al. Expert Opin Ther Targets. 2011 Jul;15(7):859-72. doi: 10.1517/14728222.2011.575362. Epub 2011 Apr 8. Expert Opin Ther Targets. 2011. PMID: 21476875 Review. - PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
Abraham J. Abraham J. Expert Rev Anticancer Ther. 2015 Jan;15(1):51-68. doi: 10.1586/14737140.2015.961429. Epub 2014 Oct 11. Expert Rev Anticancer Ther. 2015. PMID: 25306975 Review.
Cited by
- Quinolones as a Potential Drug in Genitourinary Cancer Treatment-A Literature Review.
Kloskowski T, Frąckowiak S, Adamowicz J, Szeliski K, Rasmus M, Drewa T, Pokrywczyńska M. Kloskowski T, et al. Front Oncol. 2022 Jun 8;12:890337. doi: 10.3389/fonc.2022.890337. eCollection 2022. Front Oncol. 2022. PMID: 35756639 Free PMC article. Review. - Suppression of mitochondrial respiration with local anesthetic ropivacaine targets breast cancer cells.
Gong X, Dan J, Li F, Wang L. Gong X, et al. J Thorac Dis. 2018 May;10(5):2804-2812. doi: 10.21037/jtd.2018.05.21. J Thorac Dis. 2018. PMID: 29997943 Free PMC article. - Recent Development of Fluoroquinolone Derivatives as Anticancer Agents.
Nowakowska J, Radomska D, Czarnomysy R, Marciniec K. Nowakowska J, et al. Molecules. 2024 Jul 27;29(15):3538. doi: 10.3390/molecules29153538. Molecules. 2024. PMID: 39124943 Free PMC article. Review. - Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mendes I, Vale N. Mendes I, et al. Biomedicines. 2024 Jan 19;12(1):227. doi: 10.3390/biomedicines12010227. Biomedicines. 2024. PMID: 38275398 Free PMC article. Review. - Levofloxacin might be safe to use for OSCC patients.
Aydemir L, Iplik ES, Ertugrul B, Kasarci G, Atas MN, Ulusan M, Ergen A, Cakmakoglu B. Aydemir L, et al. Med Oncol. 2021 Jun 25;38(8):87. doi: 10.1007/s12032-021-01538-2. Med Oncol. 2021. PMID: 34170451
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous